GlobalData on MSN1d
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...
Zacks Investment Research on MSN1d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated ...
Johnson & Johnson reports ‘positive’ results from Phase 2b study of icotrokinra
Johnson & Johnson announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
Protagonist reports top line results from Phase 2b study of icotrokinra
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
PharmExec22h
Icotrokinra Demonstrates Promise in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...
Johnson & Johnson (NYSE:JNJ) Reports Positive Phase 2b Trial Results For Ulcerative Colitis Treatment
Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant announcements regarding its clinical trials, particularly the ANTHEM-UC ...
Forbes28d
Anthem Medicare Supplement Review 2025
Commissions do not affect our editors' opinions or evaluations. Anthem Medicare Supplement plans offer cost-competitive choices for people who want to add coverage beyond what they receive with ...